📰 Specific Populations News
Page 2 - Specific Populations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Specific Populations. Real-time updates on events, politics, business and more.
February 1, 2024
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make...
January 30, 2024
Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved GAMMAGARD LIQUID Immune Globulin Infusion Human 10 solution as an intravenous immunoglobulin IVIG therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy CIDP.
January 29, 2024
New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin Portfolio to Meet the Needs of People Living with CIDP Approval Supported by Phase 3...
January 8, 2024
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023...
November 27, 2023
Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting...
November 14, 2023
The 76-page report, “‘They Don’t Treat Us like Human Beings’: Abuse of Imprisoned Women in Japan,” documents the abusive conditions in many women’s prisons in Japan. Government policies towards women in prison violate international human rights conventions and contravene international standards such as the United Nations Standard Minimum Rules of the Treatment of Prisoners, known as the Mandela Rules. Prison authorities use restraints on imprisoned pregnant women, arbitrarily employ ...
November 12, 2023
(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
November 12, 2023
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ...
November 12, 2023
Oral presentation delivered at the American Heart Association Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in...
November 1, 2023
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...